Overview

Our MAGE-A10 T-cell therapy is directed to a highly immunogenic member of the MAGE-A family of cancer testis antigens expressed in a number of solid tumor cell types, and the immunogenicity of the MAGE-A10 antigen has been robustly established. Any expression in cancer is often associated with higher grade tumors.

Based on our ongoing preclinical evaluation, we believe our MAGE-A10 TCR therapeutic candidate has the potential ability to bind target peptides from multiple cancer types, including lung cancer. Clinical trials for our MAGE-A10 TCR therapy initiated in late 2015. The initial clinical program will be in patients with advanced stage NSCLC.

Pipeline

Candidate Indication Partner Development Stage
Research Pre-IND Phase 1/2
MAGE-A10 TCR NSCLC Wholly Owned
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: Study initiated in Q4 2015
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Bladder, Melanoma, and Head and Neck cancer Wholly Owned
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress

Learn More About